Sysmex XN-HPC: study of reference intervals and clinical decision limits in healthy allogeneic donors mobilised with G-CSF-Reference-Cited by-同舟云学术

Sysmex XN-HPC: study of reference intervals and clinical decision limits in healthy allogeneic donors mobilised with G-CSF

Published:2024-08-24 Issue:1 Volume:24 Page:
ISSN:1591-9528
Container-title:Clinical and Experimental Medicine
language:en
Short-container-title:Clin Exp Med

Author:

Huang Lunhui,Lin Binbin,Mu Yueyi,Li Yong,Chen Miao,Zhou Yunxia,Zhu Guoqing,Jiang Erlie,Xia Yonghui

Funder

Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10238-024-01467-0.pdf

Reference31 articles.

1. Amouzegar A, Dey BR, Spitzer TR. Peripheral blood or bone marrow stem cells? practical considerations in hematopoietic stem cell transplantation. Transfus Med Rev. 2019;33:43–50.

2. Peripheral blood haploidentical allogeneic stem cell Transplantation in older adults with acute myeloid leukemia and myelodysplastic syndromes demonstrates long term survival, results from the Australasian bone marrow transplant recipient registry.

3. Sebastien B, Cheverton P, Magnin C, Aouni J, Castan R. Development and validation of a predictive model to guide the use of plerixafor in pediatric population. Bone Marrow TranspL. 2022;57:1827–32.

4. Balint MT, Lemajić N, Jurišić V, et al. An evidence-based and risk-adapted GSF versus GSF plus plerixafor mobilization strategy to obtain a sufficient CD34+ cell yield in the harvest for autologous stem cell transplants. TRANSL ONCOL. 2024;39:101811.

5. Gauntner TD, Brunstein CG, Cao Q, et al. Association of CD34 cell dose with 5-year overall survival after peripheral blood allogeneic hematopoietic cell transplantation in adults with hematologic malignancies. Transpl Cell Ther. 2022;28:88–95.